The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical pharmacologic considerations for the phase II/III dose/regimen of the investigational Aurora A kinase (AAK) inhibitor MLN8237 (alisertib): Pharmacokinetics (PK), pharmacodynamics (PD), and exposure-safety relationships.
Karthik Venkatakrishnan
Employment or Leadership Position - Millennium
Xiaofei Zhou
Employment or Leadership Position - Millennium
Jeffrey Ecsedy
Employment or Leadership Position - Millennium
Hadi Danaee
Employment or Leadership Position - Millennium
Hugh Xiao
Employment or Leadership Position - Millennium
Hongliang Shi
Employment or Leadership Position - Millennium
Diane R. Mould
Consultant or Advisory Role - Projections Research
Howard Fingert
Employment or Leadership Position - Millennium
Ely Benaim
Employment or Leadership Position - Millennium
Stock Ownership - Millennium
Robert Kleinfield
Employment or Leadership Position - Millennium
Ashley Milton
Employment or Leadership Position - Millennium